Resurgence of mucormycosis during COVID-19 pandemic



To explore the literature on corona-associated mucormycosis and explain its relevance to dentists and oral surgeons.


A literature search was carried out to identify reported cases on corona-associated mucormycosis since the start of COVID-19 pandemic.


A review of literature identified 265 published papers on CAM between March 2020 and September 2021. Careful screening of abstracts and full texts revealed 29 studies reporting case series of CAM and, 27 case reports on CAM.


A multitude of factors may be responsible for the alarming rise in the incidence of corona-associated mycosis including reduced access to routine medical services during the pandemic, injudicious use of antibiotics, steroids and nutritional supplements. Risk factors contributing to corona-associated mucormycosis need to be recognized. Dentists and oral surgeons can contribute to early recognition of corona-associated mucormycosis involving the maxilla, and palate. Prioritizing research focus on optimal management of mucormycosis may reduce the morbidity and mortality associated with this debilitating infection.


  • Explores the current literature on corona-associated mucormycosis.

  • Explains the factors contributing to development of mucormycosis in patients with Corona Virus.

  • Emphasizes the role of dentists and oral surgeons in recognition and management of rhio-orbital mucormycosis.


Mucormycosis is a fulminant, potentially fatal, opportunistic fungal infection. It affects immunocompromised patients, and its mortality rate has been reported to be as high as 80%. First described as Phycomycosis by Paltauf in 1885, the term mucormycosis was introduced by Baker in 1957 and still remains in use [ , ]. Currently, Mucorales fungi are the next most common mold pathogens after Aspergillus, leading to invasive fungal disease in susceptible patients.

Mucormycosis is primarily seen in patients with immunosuppression. Due to the increasing incidence of diabetes mellitus, cancer, and growing number of organ transplantations, the number of patients at risk for this deadly infection is increasing. Despite aggressive therapy including surgical debridement and adjunct antifungal therapy, morbidity and mortality following mucormycosis remains high. New strategies to prevent and treat mucormycosis are warranted. A better understanding of the pathogenesis and host response to mucormycosis may provide targets for novel therapeutic interventions in the future [ ].

Based on clinical presentation and involvement of typical anatomic regions, mucormycosis is classified into five clinical types namely, (i) rhino-cerebral, (ii) pulmonary, (iii) cutaneous, (iv) gastrointestinal, and (v) disseminated. These categories of invasive mucormycosis tend to occur in patients with specific defects in host defense. For example, patients with diabetes mellitus (DM) complicated by ketoacidosis typically develop the rhinocerebral form of the disease, and much more rarely develop pulmonary or disseminated disease [ ].

The rhino-orbito mucormycosis (ROM) is the most common type of mucormycosis [ , ]. The disease process starts with inhalation of the fungus into the paranasal sinuses. The fungus may spread to invade the palate, maxilla, orbit, or centrally to involve the brain. If untreated, infection usually spreads from the ethmoidal air sinuses to the orbits, resulting in the loss of extraocular muscle function and proptosis [ ]. Classically, the clinical presentation has been described as an orbital cellulitis with proptosis, and neuropathies including loss of vision.

ROM frequently involves the palate and maxilla ( Fig. 1 ). Necrotic exposure of the palatal bone may the first clinically visible manifestation of the disease and patients may initially present to dentists or oral and maxillofacial surgeons. Similarly, neuropathies involving the trigeminal or facial nerve may initially present to oral and maxillofacial surgeons ( Fig. 2 ).

Fig. 1
Maxillary necrosis following mucormycosis.

Fig. 2
Facial nerve paralysis following Mucormycosis.

Optimal management of mucormycosis is complicated due to lack of well-defined predictors of clinical response to interventions and high risk of morbidity. Mucormycosis is more commonly reported from countries with poor socio-economic profile and has not received adequate focus in contemporary clinical research. Diagnosis of mucormycosis is based on clinical assessment, and relevant laboratory investigations [ ]. Imaging techniques can provide useful information regarding the extent of specific organ involvement but are not conclusive. Histopathology, microbial identification with polymerase-chain reaction (PCR) tests are the key investigations to establish a definitive diagnosis [ ].

Current management options focus on control of risk factors and a combination of anti-fungal therapy and surgical debridement of infected tissues. Owing to its broad-spectrum antifungal activity, traditionally amphotericin B has been the antifungal agent of choice for the treatment of mucormycosis [ ]. Other options include posaconazole and isavuconazole [ ]. Adjunctive measures to manage mucormycosis include irrigation of infected tissues with Amphotericin B, hyperbaric oxygen therapy and iron chelators. However, lack of robust evidence precludes their routine use in the management of mucormycosis.

The aim of this paper is to review current evidence on Corona-associated mucormycosis (CAM) following the start of COVID-19 pandemic.

Review of literature on corona-associated mucormycosis

This paper is based on a review of published literature and did not involve collection of new data. Therefore, the study was exempt from ethics approval. Images used in this paper were obtained after an informed consent from patients.

A review of literature identified 265 published papers on CAM between March 2020 and September 2021. Careful screening of abstracts and full texts revealed 29 studies reporting case series of CAM and, 27 case reports on CAM. Table 1 summarizes the key features of CAM reported in case series. M of studies from reporting CAM were from India.

Table 1
Corona-associated mucormycosis (CAM) cases reported between March 2020 to September 2021.
Author; Year & Location Number of cases (N) Mean Age (Years) Gender Clinical Presentation
Fouad et al. ., 2020, Egypt 6 51.2 M = 6 ROCM
Arora et al., 2021, India 60 57 M = 45; F = 15 ROCM
Ashour et al., 2021, Egypt 8 53.63 M = 5, F = 3 AIFS
Bayram et al., 2020, Turkey 11 73.1 M = 9; F = 2 ROM
Bhanuprasad et al., 2021, India 164 50.52 M = 101; F = 36 ROCM
Desil et al., 2021, India 100 56 M = 64; F = 36 ROM
Deve et al., 2021, India 58 55 M = 44; F 14 ROCM
Dubey et al., 2021, India 55 53; M = 35, F = 20 ROCM
Elhamamsy et al., 2021 Multiple countries 3 67 M = 3 ROCM
Gupta et al. ., 2020, India 56 53 M = 41, F = 15 ROCM
Mishra et al., 2021, India 32 58.28 M = 17; F 15 ROM = 19;
SM = 13
Mitra et al. ., 2021,India 32 57 M = 23; F = 9 ROCM
Moorthy et al. ., 2020, India 16 54.6 M = 15, F = 1 ROCM
Nair et al., 2021, India 127 35.9 Not reported ROM
Nehara et al., 2021, India 5 59 M = 1; F = 4 ROM
Pakdel et al., 2020, Iran 15 52 M = 10; F = 5 ROM
Pradhan et al. ., 2021, India 46 48.80 M = 40, F = 6 ROM = 33; RCM = 10; Mandibular = 1; SM = 2
Ramaswami et al., 2021, India 70 44.5 M = 42; F = 28 ROM
Ravani et al., 2021, India 31 56.3 M = 20, F = 11 ROM
Roa et al., 2021, India 28 49.1 M = 22; F = 8 PNS and maxillary involvement
Saidha et al., 2021, India 6 39 M = 4; F = 2 PNS involvement
Sarkar et al., 2021,India 10 67 M = 8; F = 2 OM
Selarka et al. ., 2021, India 47 55 M = 35; F = 15 Maxillary and PNS involvement
Sen et al., 2020, India 6 60.5 M = 6 ROM
Sen et al., 2021, India 2826 51.9 M = 1993; F = 833 ROCM
Sharma et al., 2020, India 23 Not reported M = 15; F = 8 SM
Singh et al., 2021, India 13 38 M = 10; F = 3 ROM = 8; RC = 2; PNS = 2; Pulmonary = 1
Veisi et al. ., 2021, Iran 2 40 M = 1; F = 1 ROM
Only gold members can continue reading. Log In or Register to continue

Stay updated, free dental videos. Join our Telegram channel

Aug 14, 2022 | Posted by in Oral and Maxillofacial Surgery | Comments Off on Resurgence of mucormycosis during COVID-19 pandemic

VIDEdental - Online dental courses

Get VIDEdental app for watching clinical videos